Gut microbiota and cardiovascular disease: opportunities and challenges.

Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. · 2020

Read Gut microbiota and cardiovascular disease: opportunities and challenges. by Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7071638.txt.

Introduction

Kazemian and co-authors examine gut microbes in cardiovascular disease in the journal Microbiome. Coronary artery disease is the world's most common health problem and its leading cause of death. Over the past decade the gut microbiota has emerged as a player in metabolism, immunity, and this disease. Correlations between gut communities and coronary disease are easy to find; proving cause is much harder.

The review works through the possible causal roots, direct and indirect, running through microbial metabolites and through the immune system. If microbes genuinely drive part of the disease, they could become targets for prevention and treatment. Getting there needs an interdisciplinary effort, the authors argue, using advanced tools such as nanomedicine and accounting for age, sex, and ethnicity. They also warn that sequencing methods can narrow the view to bacteria alone, missing fungi, protozoa, and viruses. The piece maps a promising field and its unfinished proof.

Catalog record

CREATORKazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7071638

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Gut microbiota and cardiovascular disease: opportunities and challenges By Negin Kazemian, Morteza Mahmoudi, Frank Halperin, Joseph C Wu, Sepideh Pakpour Published in: Microbiome DOI: 10.1186/s40168-020-00821-0 ABSTRACT Abstract Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to diseases, including CAD. Although correlations have been shown between CAD and the gut microbiota, demonstration of potential causal relationships is much more complex and challenging. In this review, we will discuss the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. Uncovering the causal relationship of gut microbiota and CAD development can lead to novel microbiome-based preventative and therapeutic interventions. However, an interdisciplinary approach is required to shed light on gut bacterial-mediated mechanisms (e.g., using advanced nanomedicine technologies and incorporation of demographic factors such as age, sex, and ethnicity) to enable efficacious and high-precision preventative and therapeutic strategies for CAD. KEY POINTS - The causal relationship between gut microbiota and CAD development has yet to be confirmed. - It is imperative to understand the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. - Dynamic elements including our diet and demographic factors such as age, sex, and ethnicity can also affect our gut microbiota and CAD development and complicate this matter. - Interdisciplinary approaches are required to shed light on the factors involved in the modulation of gut microbiota and its association with CAD development. - Elucidating the system-level multifaceted web of factors involved in microbiome-mediated mechanisms and human health and disease can guide novel preventative and therapeutic interventions for CAD. INTRODUCTION High serum cholesterol (hypercholesterolemia) is a well-documented risk factor for the most prevalent form of cardiovascular disease (CVD) known as coronary artery disease (CAD) [1–3], which is one of the leading causes of morbidity and mortality worldwide [4, 5]. Other established risk factors for CVD include hypertension, diabetes mellitus, obesity, and a sedentary lifestyle [6]. The buildup of cholesterol-containing deposits (plaque) inside the artery walls can lead to atherosclerosis [7], which is expected to cause 12 million coronary deaths annually by 2030 [8]. Hypercholesterolemia can have a genetic origin [9, 10] and affect bodily functions that are mainly responsible for cholesterol homeostasis in the body, including de novo synthesis, catabolism in the liver and secretion into bile, and intestinal absorption [11]. Cholesterol in the body originates from two sources and is synthesized de novo in the liver or can enter our body via our diet and cholesterol-rich foods. About one fourth of the cholesterol in the body comes from dietary intake (exogenous) and the rest is synthesized de novo (endogenous) via the mevalonate pathway [12, 13]. The cholesterol synthesized within the body is classified as either high-density lipoproteins (HDL) cholesterol or low-density lipoproteins (LDL) cholesterol, the latter of which can enter the circulatory system and becomes a key marker of CAD [14]. By contrast, HDL cholesterol is inversely associated with CAD [15] and has anti-atherogenic functions by exerting anti-inflammatory and anti-oxidative effects and promoting reverse cholesterol transport (RCT), which can eliminate LDL cholesterol [16]. However, HDL may lose its anti-atherogenic properties and becomes pro-atherogenic (dysfunctional) under conditions such as inflammation, diabetes, and oxidative stress [16]. Moreover, elevated LDL cholesterol is a risk factor for CAD [17], which may be due to the uptake of LDL cholesterol particles by macrophages that leads to foam cells and atherosclerosis [18]. The gut lumen plays an eminent role in controlling the body’s cholesterol balance and is responsible for exogenous intake via cholesterol absorption [19]. Luminal cholesterol can come from different sources and is mainly derived from (i) our diet, (ii) bile via the hepatobiliary pathway [20], and (iii) de novo cholesterol via the transintestinal cholesterol efflux (TICE) pathway [21, 22] (Fig. 1a). In the liver, cholesterol is metabolized into bile acid and is secreted into bile via the hepatobiliary pathway where the ATP-binding cassette transporter, G5/ATP-binding-cassette transporter G8 (ABCG5/G8), plays a key role in cholesterol efflux from hepatocytes into bile [23]. TICE is an alternative route to the hepatobiliary pathway, where cholesterol from the blood can directly enter enterocytes through LDL receptors (LDL-R) and is effluxed by ABCG5/G8 and the ATP-binding cassette transporter B1 (ABCB1a/b) into the lumen [22]. The cholesterol content of the lumen is then either absorbed into enterocytes via Niemann-Pick C1-like 1 (NPC1L1) and incorporated into chylomicrons for entry into the circulatory system [19], or is reduced by gut microbiota to poorly absorbable coprostanol (5B-Cholestan-3B-ol) [24–26], which is mostly excreted. [Figure: Cholesterol, gut microbiota, and CAD. a Exogenous and endogenous sources of luminal cholesterol. b The multifaceted mechanisms involved in CAD development. The gut microbiota can directly (via metabolites) and indirectly (via the immune system) lead to CAD] Aside from the complex interplay of numerous cholesterol sources in the body, many other factors can affect cholesterol balance and CAD development including our gut microbiota. To date, associations between an altered gut microbiome composition and metabolic disorders such as obesity, diabetes mellitus, and CVD (independent of age, sex, and host genetics) [27, 28], including atherosclerosis, dyslipidemia, hypertension, and heart failure have been suggested [29–31]. Such links can be through direct (via metabolites) and indirect pathways (via the immune system) [27, 32]. The adult human gastrointestinal tract harbors 100 trillion bacteria belonging to at least several hundred species [33]. The gut microbiota plays multiple critical roles in the maintenance of their host health, including helping host nutrition and energy harvest, intestinal epithelial homeostasi s[34, 35], drug metabolism and toxicity [36], immune system response [37], and protection from pathogens [38]. These microorganisms can also generate microbial products such as uremic toxins [39], bile acids [40], trimethylamine-n-oxide (TMAO) [41], short chain fatty acids (SCFA) [42], lipopolysaccharides (LPS) [43], nitric oxide [44], vitamin K [45], vitamin B complex [46], gut hormones [47], and neurotransmitters [48], which can alter host metabolism and affect bodily functions in health and disease states. Susceptibility to atherosclerosis, for example, has been demonstrated to be transferable by microbiota transplantation in murine models [49]. To date, many infectious agents have been linked to atherosclerosis including Helicobacter pylori, Cytomegalovirus, Hepatitis C virus, Chlamydia pneumoniae, and Porphyromonas gingivalis [50]. Interestingly, a study by Mitra et al. showed that microbiota displayed differences between symptomatic and asymptomatic atherosclerotic plaques, with asymptomatic plaques having an increased abundance of host microbiome associated families including Porphyromonadaceae, Bacteroidaceae, Micrococcacaea, and Streptococcacaea [51]. In contrast, symptomatic atherosclerotic plaques contained an increased abundance of pathogenic microbiome families including Helicobacteracaea, Neisseriaceae, and Thiotrichacaea [51]. Moreover, gut microbiota dysbiosis as a result of the disruption to the overall state of gut microbiota has been associated with increased inflammation, which is linked with the development of atherosclerosis [52]. Recently, alterations in the gut microbiota and its metabolites have also been associated with hypertension and vascular dysfunction [53, 54]. Heart failure has also been associated with specific gut microbial species such as increased Escherichia coli, Klebsiella penumoniae, and Streptococcus viridans [55]. One study has shown that

Read the complete text